Merck公司推出的新药Boceprevir对丙型肝炎Hepatitis C病毒有很好的抑制效果。 这个药最早是由 Schering-Plough开发的,这个公司在2009年被 Merck 买下. Boceprevir 属于蛋白酶抑制剂,特异性的抑制hepatitis C virus 的一个蛋白酶NS3 protease ,而导致病毒蛋白不能被完全处理而无法组装和成熟. 由于丙种肝炎病毒的寄主特异性和在体内的感染过程的特殊性。该病毒目前没有有效的 体外细胞培养系统,也缺乏可以大规模筛选的动物模型,所以无法采用小分子筛选方式 。该药的开发几乎是纯粹由蛋白结构研究和binding prediction 推导开的,在对NS3 protease进行结晶之后,研究组在一些已知信息的基础上,对蛋白酶的活性基团serine 的侧链进行了抑制物设计 。在得出了最初的蛋白多肽lead 之后进行了进一步的优化, 最终得出了一个最有效的分子结构。 Federal health officials say a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years. But the agency has questions about how the drug should be combined with older medicines for the maximum effect. The Food and Drug Administration posted its review of Merck & Co. Inc.'s boceprevir ahead of a public meeting next week to consider whether to approve the medication. The meeting brings to a head more than 15 years of research to find a better therapy for a virus that infects about 3.2 million people in the U.S. FDA scientists said the two studies submitted by Merck showed patients had undetectable virus levels six months after completing treatment with boceprevir. http://www.pharmpro.com/News/FeedsAP/2011/04/fda-says-merck-dru
【在 g****1 的大作中提到】 : : Vertx has similar Hep C virus drug Telaprevir to be reviewed this week by : FDA as well.
b*e
32 楼
几个月了?
【在 b***a 的大作中提到】 : 大喜事
t*m
33 楼
FDA will review two NS3/4A protease inhibitors, Merck’s boceprevir on April 27 and Vertex’s telaprevir on April 28. Vertex is a little more aggressive in the pre-market promotions because Vertex is a company with one product and it is telaprevir. So it has got to work for them.
by
【在 x**********g 的大作中提到】 : Yes. With better safety profile.
April got to Market is already anticipate big news for Vertex, the stock is up 12% today. It's one of the most promising biotech company.
【在 t*m 的大作中提到】 : FDA will review two NS3/4A protease inhibitors, Merck’s boceprevir on April : 27 and Vertex’s telaprevir on April 28. : Vertex is a little more aggressive in the pre-market promotions because : Vertex is a company with one product and it is telaprevir. So it has got to : work for them. : : by
s*y
40 楼
FDA says Vertex hepatitis drug is highly effective By The Associated Press Tuesday, April 26, 2011 Federal health officials say a highly anticipated hepatitis C drug from Vertex Pharmaceuticals successfully treats a clear majority of patients in less time than older medicines that have been used for 20 years. The Food and Drug Administration posted its review of Vertex's telaprevir ahead of a meeting Thursday where outside experts will vote on the benefits of the drug. On Wednesday the experts will review a similar drug from Merck. Both new drugs work by blocking the enzyme protease, which allows the hepatitis virus to reproduce. The new approach represents a breakthrough from older medicines, which are designed to help the immune system fight hepatitis. FDA scientists said 79 percent of patients who added telaprevir to older medicines were virus free six months after treatment.
April to
【在 t*m 的大作中提到】 : FDA will review two NS3/4A protease inhibitors, Merck’s boceprevir on April : 27 and Vertex’s telaprevir on April 28. : Vertex is a little more aggressive in the pre-market promotions because : Vertex is a company with one product and it is telaprevir. So it has got to : work for them. : : by